Truist initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $35 price target Summit is a biotech company built around ivonescimab, the most clinically advanced asset in a novel class of drugs that has potential to surpass the most successful drug class in oncology, the analyst tells investors in a research note. The firm says two pivotal trials in lung cancer are underway, and that it thinks the data will be positive and enable ivonescimab to access the U.S. and European markets beginning in 2026. While lung cancer represents a substantial opportunity, the total addressable market for ivonescimab is much broader, contends Truist. It believes Summit could be a takeober target for a large biopharma company with the development capabilities that can maximize ivonescimab’s potential.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SMMT:
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- Summit Therapeutics initiated with an Overweight at Wells Fargo
- Summit Therapeutics initiated with a Buy at Jefferies
- Biotech Alert: Searches spiking for these stocks today
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
